Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda Campos

Pediatric Endocrinology Phoenix, AZ Medical Doctor

NPI 1053653113 CMS profile 2787917

1920 E Cambridge Ave Ste 301, Phoenix, AZ 85006

Open in the dashboard

General payments

$3,244

149 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Campos of Phoenix, AZ is reported in the CMS Open Payments database as having received $3,244 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $392 14
2024 General $544 14
2023 General $496 25
2022 General $655 26
2021 General $679 50
2020 General $150 7
2019 General $326 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Campos
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Amanda Campos were reported at $392. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Amanda Campos Pediatric Endocrinology median Middle half National median
2019 $326 $196 $68–$845 $163
2020 $150 $124 $37–$722 $114
2021 $679 $134 $35–$691 $132
2022 $655 $177 $47–$726 $149
2023 $496 $236 $75–$887 $160
2024 $544 $259 $91–$979 $164
2025 $392 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $621 50 payments
  2. Beta Bionics, Inc. $261 4 payments
  3. Tandem Diabetes Care, Inc. $207 8 payments
  4. Novo Nordisk Inc $181 11 payments
  5. Pfizer Inc. $174 10 payments
  6. Rhythm Pharmaceuticals, Inc. $173 4 payments
  7. Sanofi-Aventis U.S. LLC $168 3 payments
  8. Insulet Corporation $151 4 payments
  9. Dexcom, Inc. $149 7 payments
  10. Abbott Laboratories $148 9 payments
  11. Other $1,011 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,183 148 payments
  2. Education $61 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR $450 39 payments
  2. iLet Bionic Pancreas Automated insulin delivery system $261 4 payments
  3. iLet Bionic Pancreas Automated insulin delivery system $261 4 payments
  4. iLet Bionic Pancreas Automated insulin delivery system $261 4 payments
  5. t:slim X2 Insulin Pump with Control-IQ $191 7 payments
  6. GENOTROPIN $174 10 payments
  7. LUPRON DEPOT $171 11 payments
  8. TZIELD $168 3 payments
  9. Imcivree $142 2 payments
  10. Dexcom G6 Transmitter $126 6 payments
  11. Other $1,634 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

26

Median for Endocrinology: 1,959

Drug cost

$666

Median for Endocrinology: $890,201

Branded share of claims

0%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocortisone Generic 14 $492
Testosterone Cypionate Generic 12 $173

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
  • SANOFI-AVENTIS U.S. LLC $146
$146 — —
LUPRON DEPOT
  • AbbVie, Inc. $66
$66 — —
FENSOLVI
  • TOLMAR, INC. $17
$17 — —
Sogroya
  • Novo Nordisk Inc $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record